Teresa Ravizza

Teresa Ravizza

Auto-generated profile, based on publicly available information

Teresa Ravizza

Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan Italy

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
AVAnnamaria Vezzani
Annamaria Vezzani
SBSilvia Balosso
Silvia Balosso
TRTeresa Ravizza
Teresa Ravizza

28 March 2010 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MMMattia Maroso
Mattia Maroso
SBSilvia Balosso
Silvia Balosso
TRTeresa Ravizza
Teresa Ravizza
JLJaron Liu
Jaron Liu
EAEleonora Aronica
Eleonora Aronica
AVAnnamaria Vezzani
Annamaria Vezzani

1 January 2008 in Neurobiology of Disease
Verified
Journal Article
Closed access
TRTeresa Ravizza
Teresa Ravizza
BGBarbara Gagliardi
Barbara Gagliardi
FNFrancesco Noé
Francesco Noé
KBKarin Boer
Karin Boer
EAEleonora Aronica
Eleonora Aronica
AVAnnamaria Vezzani
Annamaria Vezzani

15 June 1999 in Journal of Neuroscience
Verified
Journal Article
Open access
AVAnnamaria Vezzani
Annamaria Vezzani
MCMirko Conti
Mirko Conti
ALAda De Luigi
Ada De Luigi
TRTeresa Ravizza
Teresa Ravizza
DMDaniela Moneta
Daniela Moneta
MSMaria Grazia De Simoni
Maria Grazia De Simoni
Using immunocytochemistry and ELISA, we investigated the production of interleukin (IL)-1β in the rat hippocampus after focal application of kainic acid inducing electroencephalographic (EEG) seizures and CA3 neuronal cell loss. Next, we studied whether EEG seizures per se induced IL-1β and microglia changes in the hippocampus using bicuculline as a nonexcitotoxic convulsant agent. Finally, to address the functional role of this cytokine, we measured the effect of human recombinant (hr)IL-1β on seizure activity as one marker of the response to kainate.Three and 24 hr after unilateral intrahippocampal application of 0.19 nmol of kainate, IL-1β immunoreactivity was enhanced in glia in the injected and the contralateral hippocampi. At 24 hr, IL-1β concentration increased by 16-fold (p< 0.01) in the injected hippocampus. Reactive microglia was enhanced with a pattern similar to IL-1β immunoreactivity. Intrahippocampal application of 0.77 nmol of bicuculline methiodide, which induces EEG seizures but not cell loss, enhanced IL-1β immunoreactivity and microglia, although to a less extent and for a shorter time compared with kainate. One nanogram of (hr)IL-1β intrahippocampally injected 10 min before kainate enhanced by 226% the time spent in seizures (p< 0.01). This effect was blocked by coinjection of 1 μg (hr)IL-1β receptor antagonist or 0.1 ng of 3-((+)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate, selective antagonists of IL-1β and NMDA receptors, respectively.Thus, convulsant and/or excitotoxic stimuli increase the production of IL-1β in microglia-like cells in the hippocampus. In addition, exogenous application of IL-1β prolongs kainate-induced hippocampal EEG seizures by enhancing glutamatergic neurotransmission.

1 August 2008 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
AVAnnamaria Vezzani
Annamaria Vezzani
SBSilvia Balosso
Silvia Balosso
TRTeresa Ravizza
Teresa Ravizza

1 July 2000 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
MSMaria Grazia De Simoni
Maria Grazia De Simoni
CPCarlo Perego
Carlo Perego
TRTeresa Ravizza
Teresa Ravizza
DMDaniela Moneta
Daniela Moneta
MCMirko Conti
Mirko Conti
AVAnnamaria Vezzani
Annamaria Vezzani